Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2007-09-24:
Avastin Achieves Impressive Rate of Curative Surgery in Patients With Advanced Colorectal Cancer
Barcelona, Spain ( PRN/ots ) - - Largest Series of Patients With Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115 - 116, Starting at 12:15 on Monday 24th September 2007 - For non - US Media (...)
2006-11-15:
Isotechnika to Announce Initial Data From Phase IIb Kidney Transplant Trial
Edmonton, Canada, November 15 ( PRN/ots ) - Isotechnika Inc. will announce initial data from its Phase IIb kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Thursday, November 16th at 8:00 a.m. ET/6:00 a.m. MT. Dr. Randall Yatscoff, Isotechnika's President (...)
2008-09-03:
GNC Continues European Expansion Through Exclusive Online Distribution Agreement with Active Nutrition International for Sales of Sports Nutrition Products in Sweden, Finland, Denmark & Norway
Pittsburgh ( PRN/ots ) - General Nutrition Centers, Inc., the largest global specialty retailer of nutritional supplements, today announced another step in its continuing expansion in Europe through an exclusive distribution agreement for online sales of GNC's private label products, its first in Europe, in (...)
2009-08-12:
Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
Hong Kong and Lake Zurich, Illinois ( PRN/ots ) - Fenwal, Inc. of Lake Zurich, Illinois, and Golden Meditech ( stock code: 801.HK ) of Hong Kong, announced today they have agreed to form a joint venture in China to focus on blood collection and (...)
2010-06-14:
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non - Hodgkin Lymphoma Receiving R - CHOP Chemotherapy
Barcelona, Spain, June 14, 2010 ( PRN/ots ) - Data presented at the 15th European Hematology Association ( EHA ) congress in Barcelona, highlights the impact of febrile neutropenia ( FN ) on chemotherapy delivery in non - Hodgkin lymphoma ( NHL ) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays (...)
2007-05-21:
Stroke, Death, and TIA Rates Significantly Reduced With Closed - Cell Carotid Stents
Paris ( PRN/ots ) - - Data From Multicentre Registry Show Significant Benefit With Closed - Cell Stents in the Treatment of Carotid Artery Stenosis Boston Scientific Corporation ( NYSE: BSX ) welcomed results from a large independent registry confirming the benefit of closed - cell stents in patients (...)
2004-09-16:
Degussa enters into research alliance with Korean partner / Targeting the next generation of materials for electronics applications
Dusseldorf ( na Originaltextservice ) - Degussa AG, Dusseldorf, Germany and LG Chem, Ltd., Seoul, Korea, have agreed on joint strategic research into the next generation of highly functional materials for electronics and IT applications. The aim is to develop products and systems solutions for and with the (...)
2006-09-04:
Markit Acquires MarketXS to Meet Client Demand for Bespoke Delivery of Data and MiFID Compliance Solutions
London and Amsterdam ( PRN/ots ) - Markit Group Limited ( "Markit" ), the leading industry source of independent data, portfolio valuations and trade processing for the OTC derivative markets, today announced it has acquired MarketXS Holding N.V. ( "MarketXS" ). MarketXS is a provider of innovative software and technology for (...)
2008-10-22:
Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany ( PRN/ots ) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non - US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first - in - class compound, BI (...)
2011-01-04:
AMP's SIVAC Initiative Supports the Creation of a Mongolian National Immunization Technical Advisory Group ( NITAG )
Paris ( PRN/ots ) - The inaugural meeting of the Mongolian National Immunization Technical Advisory Group ( NITAG ) was held at the Ministry of Health in Ulaanbaatar on December 6, 2010. The NITAG is the first of its kind in Mongolia and was established based on (...)
2007-04-27:
CHMP Adopts Positive Opinion for Alexion's Soliris( TM ) in Europe
Cheshire, Connecticut ( PRN/ots ) - - CHMP recommends marketing authorization for Soliris( TM ) ( eculizumab ) to treat all patients with paroxysmal nocturnal hemoglobinuria ( PNH ) - - First medicinal product to receive positive opinion from CHMP under Accelerated Assessment Procedure - Alexion Pharmaceuticals, Inc. ( Nasdaq: ALXN ) today announced (...)
2008-09-16:
SemBioSys Eligible to Proceed With Phase I/II Plant - Produced Insulin Trial After Submission of IND
Calgary, Canada ( PRN/ots ) - - TSX symbol: SBS SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it is eligible to proceed with its planned Phase I/II human clinical (...)
2004-11-18:
Boehringer Ingelheim Announces 24 - Week Results From Second Phase III Pivotal Study of Tipranavir
Glasgow, Scotland, November 18 ( PRN/ots ) - - RESIST - 2 Data Demonstrate Efficacy in Treatment - Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment - experienced HIV - positive patients taking tipranavir therapy achieved treatment response versus those (...)
2006-08-17:
Osteoporosis Treatment Now Approved in Europe & US for Men
Paris, France ( PRN/ots ) - - Male Osteoporosis: Neglected and Under Treated PARIS, France, August 17 /PRNewswire/ - - The US Food and Drug Administration ( FDA ) this week approved Actonel( R ) 35mg ( risedronate sodium tablets ) for 'treatment to increase bone mass in men with osteoporosis'. This (...)
2005-12-12:
PharmaMar Reports Positive Phase II Results on Aplidin( R ) in Patients With Advanced Multiple Myeloma at ASH
Madrid ( PRN/ots ) - PharmaMar today announces the results of the Aplidin( R ) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December. Aplidin reached its objective of overall response rate established in (...)
2005-11-23:
New Study of VEGF Signalling Inhibitor AZD2171 Used in the First - Line Setting for Patients With Advanced NSCLC
Alderley Park, England, November 23 ( PRN/ots ) - - First patient enrolled into double - blind, randomised, placebo - controlled study to investigate overall survival in a broad NSCLC population AstraZeneca ( NYSE: AZN ) announced today the start of recruitment into a pivotal Phase II/III study (...)
2007-10-30:
Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
Oss, The Netherlands ( PRN/ots ) - Organon, the human healthcare business unit of Akzo Nobel, today announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to (...)
2008-02-20:
Siemens Healthcare Announces Exclusive Partnership With Prowess Inc.
Concord, California ( PRN/ots ) - - Plans to Integrate Treatment Planning System with Oncology Solutions Technology Siemens Healthcare ( www.usa.siemens.com/healthcare ) announces an exclusive partnership with Prowess Inc. to develop advanced radiation oncology treatment planning software for integration into Siemens' linear accelerators. The combination of Prowess' (...)
2006-09-12:
Exubera Hailed as Innovation In Prestigious European and American Awards
New York ( PRN/ots ) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only (...)
2010-06-19:
/OFF HOLD OFF HOLD OFF HOLD - - Servier/
Rome, June 19, 2010 ( PRN/ots ) - /OFF HOLD OFF HOLD OFF HOLD - Servier, PIV395527 The following release: "Protelos( R ) ( Strontium Ranelate ) Builds Stronger Bone Compared to Bisphosphonates" is now OFF HOLD. Distribution time: 19 Jun 2010 08:15 GMT The osteoporosis treatment Protelos( R ) (...)
2009-08-31:
CRESTOR( R ) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona ( PRN/ots ) - A new analysis from the JUPITER study showed that CRESTOR( R ) ( rosuvastatin ) 20mg reduced the composite primary end point of major cardiovascular ( CV ) events ( combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes ) by 39 Prozent (...)
2006-07-25:
Remote Delivery Group Medify International Springboards Into European Healthcare
Toronto ( PRN/ots ) - Remote technology company Medify International announced today that it is building on its UK collaboration with Oracle, the world's largest enterprise software company, and expanding across Europe. Following the success of its collaborative approach with Oracle in delivering a tried and (...)
2007-11-16:
Avastin Receives Positive Opinion in Europe for First - Line Treatment of Patients With Advanced Kidney Cancer
Basel, Switzerland, November 16 ( PRN/ots ) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive recommendation for Avastin ( bevacizumab ) (...)
2009-12-21:
Medicago Reports Positive Phase I Results for its Avian Flu Pandemic Vaccine
Quebec City ( PRN/ots ) - Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus - Like Particles ( VLPs ), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine (...)
2007-10-23:
Two New Studies Provide Real World Data on Cardiovascular Events in CRESTOR Users
London ( PRN/ots ) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR( TM ) ( rosuvastatin ) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research ( ISPOR ) (...)
2006-01-19:
Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development
Basel, Switzerland and Morrisville, North Carolina ( PRN/ots ) - - Early Preclinical Data on TR - 291144 and TR - 290999 to be Presented at Major HIV Congress in February BASEL, Switzerland and MORRISVILLE, North Carolina, January 19 /PRNewswire/ - - Roche and Trimeris today announced their (...)
2008-05-31:
/K I L L K I L L K I L L - - Merck Serono/
We are advised by Merck Serono that journalists and other readers should disregard the news release "Erbitux Significantly Prolongs Survival in 1st - Line Treatment of Non - Small Cell Lung Cancer" NYSE:SRA, issued today due to premature release. This release will be reissued at (...)
2004-10-29:
FDA Approved Fosrenol Maintains Long Term Bone Health in First Ever Five Year Bone Biopsy Data for a Phosphate Binder
St Louis, Missouri ( PRN/ots ) - Shire Pharmaceuticals Group plc ( NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN ) announced that long - term treatment with FOSRENOL( R ) ( lanthanum carbonate ) for up to five years, shows no deterioration in bone health according to new data presented today for the (...)
2007-06-01:
Lilly Announces a Call for Articles Into 2007 Luminous Award
Indianapolis ( PRN/ots ) - - Luminous Award recognizes outstanding cancer journalism from outlets around the world Following the success of the inaugural Luminous Award in 2006, Lilly Oncology announced today the call for entries to Luminous 2007. The Luminous Award was created by Lilly (...)
2008-05-30:
Pertuzumab With Herceptin( R ) Shows Impressive Results in Women With Advanced HER2 - Positive Breast Cancer
Basel, Switzerland ( PRN/ots ) - New data from a Phase II trial presented at the American Society of Clinical Oncology ( ASCO ) 2008 meeting showed that half of the patients with advanced, HER2 - positive metastatic breast cancer whose disease had progressed during a Herceptin - containing regimen (...)
2010-06-07:
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD - UPON - AVON, England, June 7, 2010 ( PRN/ots ) - Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm (...)
2005-04-07:
YONDELIS( R ) Granted Orphan Drug Designation by the U.S. FDA For The Treatment of Ovarian Cancer
Madrid, Spain ( PRN/ots ) - PharmaMar announced today that its marine - derived anti - cancer drug, YONDELIS( R ) ( trabectedin ), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration ( FDA ) for the treatment of ovarian cancer. The U.S. application sponsor, is Johnson & Johnson (...)
2006-06-04:
Clinical Experience for 'Arimidex' ( anastrozole ) Passes Two Million Patient Years ( i ) Milestone
Macclesfield, England ( PRN/ots ) - - Evidence Drives More Clinicians to Choose anastrozole as Optimal Hormonal Therapy for Postmenopausal Women With Early Breast Cancer AstraZeneca announced today, from the American Society of Clinical Oncology ( ASCO ) Annual Meeting, that anastrozole has this (...)
2006-06-05:
Predictor of Response to IRESSA( TM ) ( Gefitinib ) Investigated in First Prospective Biomarker Study
Atlanta ( PRN/ots ) - - Study Provides Further Evidence That High EGFR Gene Copy Number Correlates With Increased Response to IRESSA in Advanced Non - Small Cell Lung Cancer ( NSCLC ) Patients Data announced today at the 42nd American Society of Clinical Oncology (...)
2006-08-14:
Analysis Provides Additional Data for PREZISTA as Part of HIV Combination Therapy
Toronto ( PRN/ots ) - Additional safety and efficacy data for PREZISTA( TM ) ( darunavir ) 300mg tablets, an anti - HIV medication, will be presented Tuesday, 15 August, at the 16th International AIDS Conference ( AIDS 2006 ) in Toronto, Canada. In an oral presentation, researchers will report data from (...)
2005-04-13:
Theriak Software Adopted at Central Pharmacy in Germany
Reykjavik, Iceland ( PRN/ots ) - Theriak Medication Management, a software system from TM Software for use in healthcare operations, went into commission yesterday at a central hospital pharmacy in Bottrop, a city in the Rühr district in Germany. The pharmacy serves hospitals in the nearby (...)
2010-01-14:
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Park, Illinois ( PRN/ots ) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment (...)
2007-10-31:
Breaking News About Treatment of World's Leading Cause of Adult Blindness to be Published Next Week
Brussels ( PRN/ots ) - First study to investigate the protective effect of a lipid - lowering agent on diabetic eye disease to be published on - line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease ( called diabetic retinopathy ) is the leading cause of vision loss (...)
2005-08-03:
Isotechnika Announces Interim Blinded Phase III Psoriasis Results
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis ( SPIRIT ) trial commenced on December 2, 2004 (...)
2006-08-10:
Dutch Biopharmaceutical Company AM - Pharma Strengthens Intellectual Property Position for Lactoferrin Derived Antimicrobial Peptide hLF1 - 11
Bunnik, The Netherlands ( PRN/ots ) - AM - Pharma B.V., a biopharmaceutical company engaged in the pre - clinical and early clinical development of novel compounds to treat infectious and inflammatory diseases, announces the issuance of the patent for one of its lead products, the antimicrobial peptide (...)
2006-10-23:
GenOdyssee SA Announces Research Partnership With Baxter AG
Paris ( PRN/ots ) - GenOdyssee S.A., a biotechnology company dedicated to the discovery of novel protein therapeutic products, has entered into a research and development cooperation agreement with Baxter AG. GenOdyssee will use its unique intellectual property position in the field of protein therapeutics, as (...)
2006-04-28:
Herceptin Receives Positive Opinion in Europe for Early Use in HER2 - Positive Breast Cancer
Basel, Switzerland ( PRN/ots ) - - Important Step Towards Broad Access of Herceptin for Women With Aggressive Form of Breast Cancer Roche today announced that the European Union's Committee for Human Medicinal Products ( CHMP ) has issued a positive recommendation for the use of Herceptin (...)
2009-02-13:
Study Proves Longer Prophylactic Therapy With Valcyte Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Basel, Switzerland ( PRN/ots ) - - Doubling Duration of Valcyte Therapy Provides Significant Benefit to Patients Compared to Current Standard of Care - For Non - US Media Only Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative (...)
2008-01-28:
Many More Patients Can Now Benefit From Avastin's Proven Survival Benefits
Basel, Switzerland ( PRN/ots ) - - Avastin Receives Broad Label Extension in Europe for the Treatment of Patients With Metastatic Colorectal Cancer Roche announced today that the European Commission ( EC ) has given its approval for the significantly wider use of its anti - angiogenic agent (...)
2009-04-30:
Outcome of New Mirapexin( R )/Sifrol( R ) ( Pramipexole ) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease
Ingelheim, Germany ( PRN/ots ) - - New Study Shows That Mirapexin( R )/Sifrol( R ) ( Pramipexole ) Relieves Depressive Symptoms of Parkinson's Disease ( PD ), a Common Non - Motor Symptom Affecting PD Patients' Quality of Life - For Non - US Healthcare Media To view the Multimedia News Release, go (...)
2007-11-07:
Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
Sydney, November 7 ( PRN/ots ) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes ( FIELD ) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA. - (...)
2008-11-17:
Quest Diagnostics' Laboratory in India Accredited by Two Leading Laboratory Accrediting Organizations
Madison, New Jersey and Gurgaon, India, November 17 ( PRN/ots ) - - Less than one tenth of one percent of labs in India are CAP and NABL accredited - Quest Diagnostics' laboratory also becomes one of only five labs in India to achieve NGSP (...)
2007-10-02:
International Survey Shows People Over Forty Ignore Risk of Blindness
London ( PRN/ots ) - - Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of Millions At - Risk for Glaucoma Results of a new international survey reveal that eye exams are being ignored by many aged over 40. Only two fifths of respondents had (...)
2008-09-24:
Landmark UPLIFT Study Reaffirms the Safety of Spiriva ( tiotropium ) in Patients With Chronic Obstructive Pulmonary Disease
Leuven, Belgium ( PRN/ots ) - - For Media Outside US and Canada - Prof. dr. Marc Decramer, Head of Pneumology of the University Hospitals Leuven, is Lead Investigator of the International UPLIFT Study Investigating Treatment of COPD Patients With tiotropium. Today he Elaborates on the (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Montag, 17.6.2019.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Sun, 16 Jun 2019 12:17:23 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal